Last update 05 Apr 2025

ABO-2203

Overview

Basic Info

Drug Type
mRNA encoding bispecific antibody, Bispecific T-cell Engager (BiTE)
Synonyms
ABO 2203, ABO2203
Target
CD19 x CD3
Action
modulators
Mechanism
CD19 modulators(B-lymphocyte antigen CD19 modulators), CD3 modulators(T cell surface glycoprotein CD3 modulators)
Therapeutic Areas
Immune System DiseasesNervous System DiseasesSkin and Musculoskeletal Diseases+ [2]
Active Indication
Autoimmune DiseasesIdiopathic Inflammatory MyopathiesLupus Nephritis+ [2]
Inactive Indication-
Originator Organization
Suzhou Abogen Biosciences Co., Ltd.Suzhou Abogen Biosciences Co., Ltd.
Active Organization
Suzhou Guangxin Biotechnology Co., Ltd.Suzhou Abogen Biosciences Co., Ltd.Suzhou Abogen Biosciences Co., Ltd.
Inactive Organization-
Drug Highest PhaseEarly Phase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with ABO-2203
NCT06747156
/ Not yet recruitingEarly Phase 1IIT
A Clinical Study to Investigate Safety, Tolerability, and Preliminary Efficacy of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Refractory Autoimmune Diseases
100 Clinical Results associated with ABO-2203
Login to view more data
100 Translational Medicine associated with ABO-2203
Login to view more data
100 Patents (Medical) associated with ABO-2203
Login to view more data
100 Deals associated with ABO-2203
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Autoimmune DiseasesPhase 1
China
Suzhou Abogen Biosciences Co., Ltd.Suzhou Abogen Biosciences Co., Ltd.
24 Dec 2024
Idiopathic Inflammatory MyopathiesPhase 1
China
Suzhou Guangxin Biotechnology Co., Ltd.
01 Dec 2024
Lupus NephritisPhase 1
China
Suzhou Guangxin Biotechnology Co., Ltd.
01 Dec 2024
Rheumatoid ArthritisPhase 1
China
Suzhou Guangxin Biotechnology Co., Ltd.
01 Dec 2024
Scleroderma, SystemicPhase 1
China
Suzhou Guangxin Biotechnology Co., Ltd.
01 Dec 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free